Analyst Target Price & Stock Review on Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Alliance Data Systems Corporation (NYSE:ADS)


The Wall Street analysts who cover Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares are providing price target projections on the company. They project that the shares will move to $171.375 within the upcoming year. The number they've arrived at is calculated by, long known as a provider of top-notch investment research. From the analysts polled by Zack's Research, the highest estimate stands at $221 and the lowest is at $92 for the stock. This number may be different from what First Call has published for the consensus target estimate. Analysts that routinely cover the company may use varying techniques in order to create a future target price. Because of the different methods that analysts can use, targets may differ greatly between analysts.

Analyst Ratings In View

Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for institutions and retail investors alike. This the calculated average of the actual recommendations (strong buy, hold, sell etc.) made for a given stock. The ABR is typically displayed with decimals (e.g. 1.52) versus the Zacks Rank, which is only shown in whole numbers (e.g. 1, 2, 3, etc.). This simplifies brokerage recommendations, which can become complicated. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)'s shares currently have an ABR of 1.77. A 1 rating would point to a Strong Buy, and a score of 5 would signify a Strong Sell rating. The average broker rating assists investors by providing them with a general feel for analyst sentiment on company shares.  The success of analyst predictions can be tracked for institutional investors through First Call.  Retail investors can use tools such as TipRanks or Marketbeat in order to track analyst performance. 

During this fiscal period, Street analysts are projecting $1.04 earnings/share. This represents the current Zacks consensus EPS. For the period which closed on 2016-06-30, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) dialed in an EPS of $0.93, creating a Surprise Factor of 2.2% (the difference between analyst projections and actual numbers). Curious investors will be awaiting 2016-10-27, the date when Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will release their quarterly results.  A surprise factor in either direction may result in significant stock movement immediately and in the days following the release.  Firms that consistently miss expectations can experience a downtrend over time.  Whereas stocks that consistently outperform analyst expectations, can often see positive stock movement. 

In the most recent session, Alliance Data Systems Corporation (NYSE:ADS) shares have traded -0.69%. Following the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent review, the stock has been noted $-4.56 away from the 50-day moving average of $211.40 and $-4.17 away from the 200-day moving average of $211.01. From a different angle, the stock has been recently recorded -31.90% off of the 52-week high of 303.75 and +17.10% removed from the 52-week low of 176.63. 

Currently, Alliance Data Systems Corporati has a price to earnings ratio of 25.75. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may show that the company is overvalued. A PEG Ratio near one may be viewed as fair value. The stock currently has a PEG Ratio of 0.96.

Price Target Update

Analysts polled by Thomson Reuters have set a consensus target price of $254.95 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets. This is a near-term estimation for the next 12-18 months.

BRKK is One of the Most Under the Radar Penny Stocks We've Ever Seen. View the free report here.